other_material
confidence high
sentiment positive
materiality 0.55
Oragenics submits Investigator's Brochure for Phase II trial of ONP-002 in Australia
ORAGENICS INC
- Phase II trial of intranasal neurosteroid ONP-002 for mild traumatic brain injury (mTBI); up to 40 participants enrolled across two arms.
- Trial is randomized, double-blind, placebo-controlled; nine doses over five days, first dose within 12 hours of injury.
- Prior Phase I confirmed safety and tolerability at multiple intranasal doses in healthy adults.
- No FDA-approved drug therapies currently exist for concussion, an unmet medical need.
- Interim CEO Janet Huffman anticipates final regulatory approvals in coming weeks to initiate trial.